Articles from Spherix Global Insights

Gastroenterologists are enthusiastic about Tremfya’s subcutaneous induction option in Crohn’s disease, a key potential brand differentiator, according to Spherix Global Insights

While interest in BMS’s pipeline asset is strong, some prescribers are underwhelmed by ACR20 endpoint.

EXTON, PA, March 27, 2025 (GLOBE NEWSWIRE) -- Tucker Hurtado, Vice President of Product Planning at Spherix Global Insights, has been named a 2025 Luminary by the Healthcare Businesswomen’s Association (HBA). She will be recognized at the organization’s annual Woman of the Year celebration, taking place in Chicago on May 9, 2025. 

As the IgAN market expands with the introduction of branded therapies, nephrologists express growing interest in the early-line potential of dual APRIL/BAFF inhibitors and atrasentan.

Hematologists remain undecided on the long-term role of newly launched hemophilia therapies, particularly as the industry awaits word on Sanofi’s fitusiran by the end of March.

Latest independent research from Spherix Global Insights highlights growing urgency to treat PNH with complement or factor inhibitors, shifting physician preferences, and the impact of biosimilar eculizumab entering the market.

Formalizing a longstanding collaboration to unite patient advocacy and market expertise to drive advancements in kidney patient care.

Rheumatologists’ perceptions of Bimzelx outperform analogue launches of Rinvoq, Skyrizi, and Tremfya in psoriatic arthritis at the three months post-launch mark, according to Spherix Global Insights.

Analysis of over 1,000 chronic kidney disease patient charts shows GLP-1 receptor agonist use nearly doubling from 2023 to 2024.

Despite greater physician pre-approval familiarity with Omvoh compared to J&J Innovative Medicine’s Tremfya, gastroenterologists favor Tremfya over Omvoh for Crohn’s disease

Currently, many lupus nephritis treating rheumatologists and nephrologists delay initiating triple therapy, with a significant portion deferring a triple therapy regimen until an initial failure.

Spherix Global Insights Announces New Study on Impact of Inflation Reduction Act (IRA) on Specialty Practices and Key Insights for Biopharmaceutical Companies in 2025.

Spherix Global Insights’ analysis of over 200 PNH patient records reveal current treatment patterns and opportunities for emerging therapies, including Fabhalta (Novartis), Voydeya (AstraZeneca/Alexion), and PiaSky (Genentech/Roche).

Findings from Spherix Global Insights show that practitioners consider nearly half of their C3G patients to be potential candidates for Fabhalta or Empaveli, if approved.

Future intensified intra-class competition among Omvoh, Skyrizi and Tremfya is expected as each brand attempts differentiation.

Spherix Global Insights’ White Paper Highlights Market Expansion and Strategies for Opportunities in HS.

US nephrologists estimate half of all FSGS patients are not optimally managed, according to Spherix Global Insights.

Although CSL Behring’s Hizentra (IgPro20) is touted as a key pipeline agent to watch, rheumatologists currently prefer AstraZeneca’s Saphnelo (anifrolumab), while dermatologists favor Priovant Therapeutics' brepocitinib.

With the potential rise of new oral agents, dermatologists are increasingly optimistic about safer, more convenient treatment options for psoriasis, according to Spherix Global Insights.

Incorporation of gene therapies, such as Beqvez (Pfizer), Hemgenix (CSL Behring) and Roctavian (BioMarin), and potential future approvals of fitusiran (Sanofi) and Mim8/denecimig (Novo Nordisk) will further drive the increasingly dynamic hemophilia markets.

Following positive topline results from the Phase III REGENCY trial, Gazyva is positioned to compete with Benlysta and Lupkynis in the lupus nephritis treatment landscape, pending approval.

Despite keen interest in BAFF-R inhibition, rheumatologists favor BMS’ Sotyktu (deucravacitinib) as the leading therapy in development for Sjögren’s.

With Tremfya also securing approval in UC earlier this month, competition promises to be fierce among the IL-23s, according to Spherix Global Insights.

Comprehensive market insights across over 40 indications in dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology, providing financial firms with the tools to evaluate brand launches and project market evolution.

US gastroenterologists more in favor of biosimilars than rheumatology and dermatology counterparts

Despite favorable views on litifilimab, AbbVie’s Rinvoq and BMS’ Sotyktu capture the most prescriber interest for approval, according to Spherix Global Insights.

While reported use of Sanofi/Regeneron’s Dupixent has declined with the adoption of LEO’s Adbry, Pfizer’s Cibinqo, and AbbVie’s Rinvoq, the overall population receiving advanced treatments is on the rise, according to Spherix Global Insights.

Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as their preferred asset.

New research conducted by Spherix Global Insights highlights opportunities for genetic therapies (Casgevy, Lyfgenia, Zynteglo) and emerging pipeline agents (including mitapivat, etavopivat, inclacumab and others).

With few treatment options for patients, hematologists look to pipeline agents such as Johnson & Johnson’s nipocalimab and Novartis’ ianalumab to improve patient outcomes, according to Spherix Global Insights.

US retinal specialists identify 4D Molecular Therapeutics’ 4D-150, Adverum Biotechnologies’ Ixo-vec, and Johnson & Johnson’s JNJ-1887 as most likely pipeline candidates for prescription if approved.

Impacts of Eohilia’s short-term 12-week label are still unfolding, but prescribers express interest in continuing consecutive treatment courses.

New brands aiming to enter the refractory epilepsy market may face challenges achieving desired penetration without improved general neurologist education efforts, according to Spherix Global Insights.

Ophthalmologists are cautious about prescribing the current geographic atrophy (GA) treatment options Syfovre and Izervay, introduced in 2023 as the first-ever therapy for GA, according to Spherix Global Insights.

Spherix Global Insights releases market landscape evolution study paired with new research tracking familiarity and uptake of Novartis’ Fabhalta and Alexion/AstraZeneca’s Voydeya.

New prescriptions for Vabysmo and Eylea HD outpace reported current brand share, indicating further growth of the brands, according to Spherix Global Insights.

Leigh Anne Siino joins executive team to accelerate company’s revenue growth.

Pending regulatory submission, Fabhalta (iptacopan) could become the first approved therapy for C3G, addressing a significant unmet need in nephrology, according to Spherix Global Insights.

As treatment strategies evolve, rheumatologists are refining SLE care with targeted biologics, driving a paradigm shift in lupus management, according to Spherix Global Insights.

Despite enthusiasm for Skyrizi, key updates for various developmental assets in ulcerative colitis were released at Digestive Disease Week, holding the potential to impact sentiments.

Spherix diversifies portfolio with strategic entry into classical hematology, tapping into a specialty with a high unmet patient need and expansive market growth.

US Neurologists express enthusiasm for new ways to administer current treatments and future disease modifying therapies, according to Spherix Global Insights.

Pending trial results supporting prescribers’ efficacy and safety demands, gene therapies are poised to capture upwards of one-fifth of the AMD, GA and DME markets, according to Spherix Global Insights.

Data from Spherix Global Insights' second annual EU IgAN patient chart audit indicates that even with the EMA approval of FILSPARITM (sparsentan), opportunities for pipeline agents to make an impact remain.

According to Spherix Global Insights, US rheumatologists are most likely to prefer Bimzelx’s dual IL-17A/F pathway as the most efficacious of all interleukins available in PsA.

Excitement grows as the FDA's first approval for MASH treatment nears commercialization, according to Spherix Global Insights.

Takeda’s line extension has outpaced other concurrent launches in adoption and familiarity three months post launch, according to Spherix Global Insights.

Research conducted by Spherix Global Insights reveals Retinal Specialists likely to adopt gene therapies.

Spherix Global Insights’ fourth annual IgAN patient chart audit reveals continued shifts in the IgAN treatment paradigm with the use of SGLT2 inhibitors, TARPEYO (Calliditas), and FILSPARI (Travere Therapeutics).

Spherix Global Insights captures neurologists’ reactions within 48 hours of these pivotal announcements.

Although crowded, the RA market contains clear pathways for existing players and new entrants to navigate the evolving landscape and expand their market share, according to Spherix Global Insights.

Adoption of Leqembi is even slower than expected.

Earlier screening will be needed in the age of biomarkers.

Navigating the landscape of Wet AMD Therapies During AMD Awareness Month

The addition of UCB’s Bimzelx in the EU and pending US approval adds to the growing momentum of the class, first established by Novartis’ Cosentyx and Eli Lilly’s Taltz, according to Spherix Global Insights.

Exton, PA, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Colleagues from Spherix Global Insights partnered with Cheeriodicals to assemble and deliver care packages to dialysis patients at local dialysis clinics in West Chester and Phoenixville, PA.

Despite the expanded armamentarium, Cosentyx has not impacted dermatologists’ perceived unmet need for new HS treatment options, according to Spherix Global Insights.

Analysis of 1,052 chronic kidney disease non-dialysis patient charts reveals continuous growth in SGLT2 inhibitor use and expanding opportunities for MRAs and GLP-1s, according to Spherix Global Insights.

According to Spherix Global Insights’ first market landscape study on Huntington’s disease, neurologists are staking their hopes on gene therapy.

Ophthalmologists’ reservations about using Syfovre in Geographic Atrophy are more limited to “new start” patients, according to Spherix Global Insights.

Efficacy and safety of pipeline multiple sclerosis assets viewed as increasingly important characteristics, according to Spherix Global Insights.

EVRENZO’s advantages of being first-to-market and possessing a broader label are likely to be key factors influencing VAFSEO uptake, according to the latest update from Spherix Global Insights.

US dermatologists’ perceptions and experience with Sotyktu likely impacting their take on the entire TYK2 class for the treatment of plaque psoriasis.

Spherix Global Insights find JAK inhibitors, led by AbbVie’s Rinvoq, establishing significant footholds in both first and later line UC treatment.

Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market lead over Litfulo.

Prior to launch, prescribers estimate that TNF inhibitors are likely to bear the greatest brunt of increased adoption of the newest market entrants, according to Spherix Global Insights

Lupus patients desire more targeted information on specific treatments available, underscoring an opportunity for the pharmaceutical industry to play a more pivotal role in patient education.

Gene therapies and LRRK2 inhibition are at the forefront of prescribers' interest, highlighting the need for a truly disease modifying therapy.

Despite Vabysmo’s gains in 2023, Eylea HD will prove to be a formidable force in the coming year.

According to Spherix Global Insights, US nephrologists have expressed a high level of enthusiasm for Novartis' iptacopan and atrasentan, as well as Otsuka’s sibeprenlimab, placing them at the forefront of their most anticipated products awaiting approval for the treatment of IgAN.

Despite overall biologic growth in both geographies, use of advanced systemic treatments in the US outpaces the EU5.

Analysis of 1,025 recently switched PsA patients reveals second- or later-line usage of IL-17, IL-23, and JAK inhibitors growing in popularity.

Exton, PA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights, a trusted leader in pharmaceutical market research, is delighted to announce the launch of its latest product, Patient Chart Dynamix™. This innovative offering represents a significant advancement from the previously acclaimed service, RealWorld Dynamix™, featuring enhanced customization and insights. This new and improved solution is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Data reveal the “why” behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists’ attitudinal and demographic data, connecting trends at the patient level to the prescribing physicians. 

Pharmaceutical industry veteran Dan Barton to serve as Chief Executive Officer

Boehringer Ingelheim's Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber future projections show little differentiation in use among the recent entrants.